Thiazolidinedione derivative and its use as antidiabetic

Details Thiazolidinedione derivative and its use as antidiabetic Thiazolidinedione derivative and its use as antidiabetic

2008-04-15

2008-04-15

Morris, Patricia L. (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

11458471

ABSTRACT:
A polymorphic form of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt (the “Polymorph”) characterised in that it provides: (i) an infra red spectrum containing peaks at 1752, 1546, 1154, 621, and 602 cm−1; and/or (ii) a Raman spectrum containing peaks at 1751, 1243 and 602 cm−1; and/or (iii) a solid-state nuclear magnetic resonance spectrum containing peaks at 111.9, 114.8, 119.6, 129.2, 134.0, 138.0, 144.7, 153.2, 157.1, 170.7, 172.0, and 175.0 ppm; and/or (iv) an X-ray powder diffraction (XRPD) pattern which gives calculated lattice spacings of 6.46, 5.39, 4.83, 4.68, 3.71, 3.63, 3.58, and 3.48 Angstroms; a process for preparing such a compound, a pharmaceutical composition containing such a compound and the use of such a compound in medicine.

REFERENCES:
patent: 5708012 (1998-01-01), Olefsky
patent: 5741803 (1998-04-01), Pool et al.
patent: 5002953 (1999-03-01), Hindley
patent: 5910592 (1999-06-01), Pool et al.
patent: 2002/0099081 (2002-07-01), Sasse et al.
patent: 2003/0120078 (2003-06-01), Sasse et al.
patent: 1277965 (2000-12-01), None
patent: 0306228 (1999-11-01), None
patent: 1468997 (2004-10-01), None
patent: 9310254 (1993-03-01), None
patent: 9405659 (1994-03-01), None
patent: 9521603 (1995-08-01), None
patent: 9855122 (1998-12-01), None
patent: 0031095 (1999-06-01), None
patent: 9931093 (1999-06-01), None
patent: 9931094 (1999-06-01), None
patent: 0064892 (2000-11-01), None
patent: 0064896 (2000-11-01), None
patent: 0226737 (2002-04-01), None
patent: 0462667 (2004-07-01), None
patent: 0485435 (2004-10-01), None
patent: 0521541 (2005-03-01), None
Brittain, “Polymorphism in Pharmaceutical Solids”, NY:Marcel Dekker, Inc 1999, p. 185.
“A Bioequivalence Study Comparing Tablets Manufactured with the 8 mg Anhydrate Form IV (ANF4) to the Commercial Anhydrate Form I (ANF1) of Rosiglitazone Maleate.” Clinical Trial Registry Report for Study No. BRL49653C/300, Oct. 27, 2005. http://ctr.gsk.co.uk/Summary/Rosiglitazone/l—49653—300.pdf.
Phadnis et al. Journal Pharmaceutical and Biomedical Analysis, vol. 15, pp. 929-943 (1997).
Chakravarty et al. International Journal of Pharmaceutics, vol. 288, pp. 335-348 (2005).
Brittain, “Polymorphism in Pharmaceutical Solids”, NY:Marcel Dekker, Inc. 1999, pp. 1-2.
Haleblian et al. J. Pharm. Sci., 58(8):911-929 (1969).
Cantello et al. Bioorg. & Med. Chem. Ltr., 4(10):1181-1184 (1994).
Chem. & Engineering News, Feb. 2003, pp. 32-35.
U.S. Pharmacopia #23, National Formulary #18 (1995), pp. 1843-1844.
Muzaffar et al. J. of Pharmacy (Lahore) (1979), 1(1), pp. 59-66.
Jain et al., Indian Drugs, 1986, 23(6): 315-329.
Taday et al. J. Pharmaceutical Sciences, 92(4), Apr. 2003, pp. 831-838.
Concise Encyclopedia, Walter de Gruyter Berline, NY, 1994, pp. 872-873.
Otsuka et al., Chem. Pharm. Bull. 47(6), 852-856 (1999).
Doelker et al., Ann. Pharm. Fr. 2002, 60: 161-176.

Affiliated with

Also associated with

Rating

Thiazolidinedione derivative and its use as antidiabetic does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Thiazolidinedione derivative and its use as antidiabetic, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiazolidinedione derivative and its use as antidiabetic will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3922048